Clinical trial • Phase I • Oncology
REGN5054 for Advanced solid tumor
Phase I trial of REGN5054 for Advanced solid tumor. None/Not specified-controlled. 40 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced solid tumor
- Trial Stage
- Phase I
- Drug Modality
- Radiopharmaceutical | Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 30-08-2024
- First CTIS Authorization Date
- 17-09-2024
Trial design
None/Not specified-controlled Phase I trial across 1 site in Netherlands.
- Comparator
- None/Not specified
- Target Sample Size
- 40
Recruitment
- Planned Sample Size
- 40
- Recruitment Window Months
- 55
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 40
Netherlands
- Earliest CTIS Part Ii Submission Date
- 09-09-2024
- Latest Decision Or Authorization Date
- 10-03-2025
- Processing Time Days
- 182
- Number Of Sites
- 1
- Number Of Participants
- 40
Sites
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Medical Oncology
- Principal Investigator Name
- Elisabeth de Vries
- Principal Investigator Email
- e.g.e.de.vries@umcg.nl
- Contact Person Name
- Elisabeth de Vries
- Contact Person Email
- e.g.e.de.vries@umcg.nl
Sponsor
Primary sponsor
- Full Name
- Regeneron Pharmaceuticals Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- 89Zr-DFO-REGN5054
- Active Substance
- REGN5054
- Modality
- Radiopharmaceutical | Monoclonal antibody
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.